Abstract
BackgroundThe requirement for luteal phase support (LPS) in stimulated IVF cycles is well established, however drug choice, and route of administration and duration of use are not. This report evaluates patients’ preference and satisfaction by using either vaginal or intramuscular (IM) progesterone (P) supplementation for luteal phase support after in vitro fertilization and embryo transfer (IVF-ET).MethodsIt is a prospective cohort study done in a reproductive and infertility unit in a tertiary care hospital from March 2013 through February 2015 for four hundred and nine patients undergoing IVF-ET. Patients were allowed to choose either vaginal or IM P for LPS. Patient preference and satisfaction, as well as differences in clinical pregnancy rates between the two groups were assessed at one or two time points throughout the study.ResultsThere were no statistically significant differences in the patients’ characteristics and clinical outcomes between the two groups. There were 88 pregnancies (38.8%) among patients treated with vaginal p and 62 pregnancies (34%) among IM P patients. Average satisfaction score at the pregnancy test and ultrasound (U/S) visits was similar between both groups.ConclusionsPatients’ satisfaction and pregnancy rates were similar between vaginal and IM P supplementation.
Highlights
The requirement for luteal phase support (LPS) in stimulated In vitro fertilization (IVF) cycles is well established, drug choice, and route of administration and duration of use are not
American Society for Reproductive Medicine (ASRM) Position Statement asserts that, “based on available data, progesterone supplementation in IVF cycles yields significantly higher pregnancy rates compared with placebo or no treatment and lower risks for ovarian
A recent Cochrane meta-analysis discussing luteal phase support for Assisted reproductive technology (ART) cycles confirmed that P has a significantly positive effect on clinical pregnancy, live birth and on-going pregnancy rates [3].The pharmacological properties are different according to the route of P administration
Summary
The requirement for luteal phase support (LPS) in stimulated IVF cycles is well established, drug choice, and route of administration and duration of use are not. This report evaluates patients’ preference and satisfaction by using either vaginal or intramuscular (IM) progesterone (P) supplementation for luteal phase support after in vitro fertilization and embryo transfer (IVF-ET). American Society for Reproductive Medicine (ASRM) Position Statement asserts that, “based on available data, progesterone supplementation in IVF cycles yields significantly higher pregnancy rates compared with placebo or no treatment and lower risks for ovarian. A recent Cochrane meta-analysis discussing luteal phase support for ART cycles confirmed that P has a significantly positive effect on clinical pregnancy, live birth and on-going pregnancy rates [3].The pharmacological properties are different according to the route of P administration. A recent systematic review and meta-analysis showed that there were no statistically significant differences in live birth rates between IM and vaginal preparations [3]. Different vaginal formulations like gel, insert, ring and suppositories resulted in similar pregnancy rate and live birth rate [8, 9]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
